Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To demonstrate that BI 201335 does not prolong the QT interval more than placebo.
To assess the tolerability of 1200 mg of BI 201335 as single dose in female subjects
(double-blind, randomised, placebo-controlled) before inclusion of female subjects in the
cross-over part of the trial.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination